You are viewing content for the region United States

Certain BTG products may not be available within the chosen location and indications may differ from your country's approved use.

Change to Canada »
Remain viewing United States »

This website is intended for US Healthcare Professionals only

Mechanism of Action

DigiFab® Digoxin Immune Fab (Ovine) has an affinity for digoxin in the range of 109 to 1010 M-1, which is greater than the affinity of digoxin for its sodium pump receptor, the presumed receptor for its therapeutic and toxic effects. When administered to an intoxicated patient, DigiFab® Digoxin Immune Fab (Ovine) binds to molecules of digoxin, reducing free digoxin levels, which results in a shift in the equilibrium away from binding to the receptors, thereby reducing cardio-toxic effects. Fab-digoxin complexes are then cleared by the kidney and reticuloendothelial system.1

Read about efficacy of DigiFab® »

References

  1. DigiFab® [prescribing information]. BTG International Inc. January 2012.

To report an adverse event or for 24-hour medical information, call 1-877-377-3784